Impact of Clinical Pharmacist on the Pediatric Intensive Care Practice: An 11-Year Tertiary Center Experience

Sandeep Tripathi1, Heidi M Crabtree2, Karen R Fryer1

  • 1Department of Pediatric Critical Care Medicine.

Insights

Increased pharmacist presence in pediatric intensive care units (PICUs) led to more interventions and fewer errors. This enhanced care for critically ill children, reducing central line infections and improving patient outcomes.

Area of Science:

  • Pediatric critical care medicine
  • Clinical pharmacy practice
  • Patient safety

Background:

  • Multidisciplinary care is crucial in complex pediatric intensive care units (PICUs).
  • Long-term data on pediatric clinical pharmacist interventions and their impact are limited.
  • Understanding the role of pharmacists in PICU practice is essential.

Purpose of the Study:

  • To describe the role and impact of pediatric clinical pharmacists in the PICU.
  • To analyze pharmacy interventions and their effect on patient care and outcomes.
  • To evaluate changes in practice with increased pharmacist presence.

Main Methods:

  • Retrospective review of pharmacy interventions in a PICU from 2003-2013.
  • Comparison of patient demographics and outcomes between periods with varying pharmacist presence (2003-2007 vs. 2008-2013).
  • Analysis of intervention acceptance rates and types.

Main Results:

  • Over 27,000 pharmacist interventions were recorded, with nearly 80% accepted.
  • Interventions prevented over 5,800 order entry errors.
  • Increased pharmacist presence correlated with decreased central line infections and entry rates.
  • Patients requiring pharmacy involvement were younger, sicker, with longer ICU/hospital stays.

Conclusions:

  • Enhanced pharmacist presence in the PICU is linked to increased interventions and reduced adverse drug events.
  • Pharmacist participation in rounds and order entry significantly improves care for critically ill children.
  • The role of clinical pharmacists in PICUs should be actively encouraged and expanded.
Abstract

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
474
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
377
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
745
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
335
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
782
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
72